Sheppard Mullin Advised Sanara MedTech in License and Distribution Agreement with Biomimetic Innovations
The firm represented medical technology company, Sanara MedTech, in executing an exclusive license and distribution agreement with Biomimetic Innovations (BMI), a privately held medical device company headquartered in Shannon, Ireland. As part of the deal, Sanara has acquired the exclusive U.S. marketing, sales and distribution rights to OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler, as well as a hardware agnostic adjunctive internal fixation technology featuring novel delivery to promote targeted application of OsStic, for use in fracture management. In tandem, Sanara agreed to contribute up to €8.0 million in cash to BMI in exchange for approximately 12.5 percent of BMI’s outstanding equity.
The deal team was led by Houston partner Steve Peterson and included partner Jaime Choi.
Click here to read more.